vaccine adjuvant comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
== Chemistry == The chemical structure of suvomipic was originally undisclosed for a time. The drug has been patented and its structure was initially said to be known only to Pelage Pharmaceuticals. The company has also patented and published on other MPC inhibitors such as JXL069 and JXL082. They are (E)-2-cyano-3-(1H-indol-3-yl)acrylic acids and related analogues. Suvomipic was said to be neither JXL069 nor JXL082. The drug-related properties of certain related MPC inhibitors like UK-5099 (JXL001) are said to be incompatible with therapeutic use. In July 2026, the INNTooltip International Nonproprietary Name of suvomipic was published and revealed it to in fact be JXL069.
=== ITV === In 2007, Willis presented ITV2 spin-off series I'm a Celebrity...Get Me Out of Here! NOW! with her husband Matt before departing in 2008. She presented numerous episodes of The Hot Desk on ITV2 between 2008 and 2014. In September 2012, Willis became a permanent presenter on This Morning, presenting segments in The Hub, taking over from Coleen Nolan. The feature was axed in 2014. She was also a stand-in presenter on the main show when Holly Willoughby or Ruth Langsford were absent and returned to guest present the show with Rylan Clark-Neal in 2018. Willis hosted two series of the ITV2 reality show Girlfriends in 2012 and 2013. On 16 November 2012, Willis was a guest anchor Loose Women and has since presented on several occasions as a stand-in presenter. In November 2013, Willis guest presented an episode of The Paul O'Grady Show while O'Grady was away. In June 2013, Willis co-presented the ITV game show Prize Island with Alexander Armstrong. In February 2015, Willis was a team captain on the six-part ITV2 comedy panel show Reality Bites, hosted by Stephen Mulhern. On 2 July 2015, it was announced that Willis would present a new three-part series for ITV called What Would Be Your Miracle, about modern miracles. The series began on 28 April 2016. In January 2017, The Voice UK moved from BBC One to ITV. It was confirmed on 9 June 2016 that Willis would present the series after co-hosting three previous series on the BBC. She also presented two series of The Voice Kids on ITV since 2017. In January 2017, she presented The BRITs Are Coming live on ITV.
Chondronectin is a high molecular weight collagen matrix protein (~180 kDa), or also known as a glycoprotein, and is most commonly found in human synovial fluid. It is mainly responsible for binding chondrocytes and collagen II substrates together in the extracellular matrix (ECM). Chondronectin is characterized as a trimeric protein, that is linked with disulfide bonds. It also has been noted to appear compact and globular in nature. Chondronectin is responsible for helping anchor chondrocytes, bearing mechanical forces and even maintaining homeostasis on a physiological level. Chondronectin works within tissue, where it joins other proteins to build a strong but flexible framework. This structure helps keep joints stable during movement and repeated pressure. Without adhesive matrix proteins like chondronectin, cartilage tissue would have a harder time handling everyday mechanical stress. Chondronectin acts as a strong binding protein inside the body's joints. It helps attach important cartilage cells directly to tough collagen fibers. These cells main responsibility is maintaining healthy cartilage tissue. This protein helps the surrounding tissue structure stay firm and stable while keeping the cartilage properly organized. Without this important connection, the framework of the joins could gradually lose stability. The protein has a three part molecular shape that helps keep it structurally stable. It remains strong while interacting with nearby matrix tissues and surrounding support components.
Indium has 39 known isotopes, ranging in mass number from 97 to 135. Only two isotopes occur naturally as primordial nuclides: indium-113, the only stable isotope, and indium-115, which has a half-life of 4.41×1014 years, four orders of magnitude greater than the age of the Universe and nearly 30,000 times greater than half-life of thorium-232. The half-life of 115In is very long because the beta decay to 115Sn is spin-forbidden. Indium-115 makes up 95.7% of all indium. Indium is one of three known elements (the others being tellurium and rhenium) of which the stable isotope is less abundant in nature than the long-lived primordial radioisotopes. The stablest artificial isotope is indium-111, with a half-life of approximately 2.8 days. All other isotopes have half-lives shorter than 5 hours. Indium also has 47 meta states, among which indium-114m1 (half-life about 49.51 days) is the most stable, more stable than the ground state of any indium isotope other than the primordial. All decay by isomeric transition. The indium isotopes lighter than 113In predominantly decay through electron capture or positron emission to form cadmium isotopes, while the indium isotopes heavier than 113In predominantly decay through beta-minus decay to form tin isotopes.
Assam Asimov (アサム・アシモフ, Asamu Ashimofu) and Mugi Grafton (ムギ・グラフトン, Mugi Gurafuton): Two of Reidlich's underlings who work undercover in S.P.D.'s Earth unit as Neo Deka Red (ネオデカレッド, Neo Deka Reddo) and Neo Deka Yellow (ネオデカイエロー, Neo Deka Ierō), respectively, and appear exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After. After failing to kidnap Carrie and being defeated by Deka Blue, Green, Yellow, and Pink, Reidlich forcibly converts Asimov and Grafton into energy to power his Neo Hyper Muscle Gear. Assam Asimov and Mugi Grafton are portrayed by Rakuto Tochihara (栩原 楽人, Tochihara Rakuto) and Mizuho Hata (秦 瑞穂, Hata Mizuho), respectively. Clementian Carrie (クレメント星人キャリー, Kuremento Seijin Kyarī): A girl from Planet Clement, whose inhabitants can enter the bodies of others for concealment, who appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After. Two years prior, she and her father accidentally stumbled onto Kruger discovering Kight Reidlich's corruption. After Reidlich killed Carrie's father, Kruger told Carrie to find his team. She went into hiding before eventually coming to Earth in the present. Upon finding the Dekarangers, they escort her to Planet Gowashichoru before confronting Reidlich. Carrie is portrayed by Rino Kobayashi (小林 里乃, Kobayashi Rino). Rui Edogawa (江戸川 塁, Edogawa Rui): A rookie S.P.D.
Sources: en.wikipedia.org
=== Legal status === In May 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ablymico, indicated for weight management as an adjunct to a reduced-calorie diet and increased physical activity. The applicant for this medicinal product is STADA Arzneimittel AG. Ablymico is a hybrid medicine of liraglutide (Saxenda), which has been authorized in the European Union since March 2015. Ablymico contains the same active substance as Saxenda, but it is chemically synthesized, whereas the active substance in the reference products is of biological origin. Ablymico was authorized for medical use in the European Union in July 2026. In May 2026, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Liraglutide Stada, intended for the treatment of insufficiently controlled type 2 diabetes. The applicant for this medicinal product is STADA Arzneimittel AG. Liraglutide Stada is a hybrid medicine of liraglutide (Victoza), which has been authorized in the European Union since June 2009. Liraglutide Stada contains the same active substance as Victoza, but it is chemically synthesized, whereas the active substance in the reference products is of biological origin.
The resulting roGFP variants, named roGFP1-R1 through roGFP1-R14, are much more suitable for live-cell imaging. The roGFP1-R12 variant has been used to monitor redox potential in bacteria and yeast, but also for studies of spatially-organized redox potential in live, multicellular organisms such as the model nematode C. elegans. In addition, roGFPs are used to investigate the topology of ER proteins, or to analyze the ROS production capacity of chemicals.
The working model, which was created using ESyPred3D computer programming, is a horseshoe shape with a β-sheet lining the interior and an α-helix or β-turn lining the exterior. The model also shows an Ig-like domain. In other proteins, the junction between this and the C-terminus of the LRR domain has proven to be a binding site for tetramer formation. Therefore, this may be the binding site for the second 83 kDa subunit of the enzyme, while the active subunit is thought to interact on the interior of the horseshoe shape. The catalytic subunit is shaped like a pear. Its first domain at the N-terminus is spherical and consists of 319 amino acids. It also contains the catalytic and substrate binding areas and is thus referred to as the carboxypeptidase domain. This domain consists of two disulfide bridges, which leaves one unpaired cysteine which extends into the interior portion of the molecule. It has a central 8 stranded β-sheet which is surrounded by 9 α-helices which, in general, run antiparallel to the sheets. The domain has a mostly hydrophobic core. The second C-terminus domain is cylinder-shaped and made up of 79 residues. It is a β-sandwich transthyretin (TT) domain with a hydrophobic core. It was previously thought that the active unit was not glycosylated; however, the structure shows three residues O-linked to N-acetyl-glucosamines. The area that binds to the regulatory subunit was determined to be the interface between these two domains.
=== Gibbs–Donnan effect === In ion exchange chromatography, the Gibbs–Donnan effect is observed when the pH of the applied buffer and the ion exchanger differ, even up to one pH unit. For example, in anion-exchange columns, the ion exchangers repeal protons so the pH of the buffer near the column differs is higher than the rest of the solvent. As a result, an experimenter has to be careful that the protein(s) of interest is stable and properly charged in the "actual" pH. This effect comes as a result of two similarly charged particles, one from the resin and one from the solution, failing to distribute properly between the two sides; there is a selective uptake of one ion over another. For example, in a sulphonated polystyrene resin, a cation exchange resin, the chlorine ion of a hydrochloric acid buffer should equilibrate into the resin. However, since the concentration of the sulphonic acid in the resin is high, the hydrogen of HCl has no tendency to enter the column. This, combined with the need of electroneutrality, leads to a minimum amount of hydrogen and chlorine entering the resin.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.